Finansielle resultater 1. kvartal 2024
| Selskabsmeddelelse nr. 31 |
Nettoresultat på 670 mio. kr. og egenkapitalforrentning på 21,1 %
Regnskabet for 1. kvartal 2024 viser et meget tilfredsstillende nettoresultat på 670 mio. kr. og en egenkapitalforrentning på 21,1 %. Bankens basisindtægter realiseres 174 mio. kr. højere end samme periode sidste år, hvilket primært kan henføres til stigning i nettorenteindtægter. Sammenlignet med samme periode sidste år er banken lykkedes med at vokse det samlede forretningsomfang med 3 % (å/å) med en underliggende vækst i udlån på 2 % og i indlån på 4 %.
I forhold til bankens kunder er der igen grund til at glæde sig over den stærke kreditkvalitet inden for både privat- og erhvervskunder, der betød nettotilbageførsel af nedskrivninger på 32 mio. kr. i 1. kvartal 2024. Dette samtidig med, at de ledelsesmæssige skøn i kvartalet var forøget med 39 mio. kr. primært relateret til fortsat usikkerhed omkring konjunkturafmatning og en kommende CO2-afgift på landbrug.
Spar Nord har således fået en god start på jubilæumsåret 2024, der resultatmæssigt fortsat forventes at blive det næstbedste resultat i bankens 200-årige historie, siger adm. direktør Lasse Nyby.
Spørgsmål i forbindelse med denne meddelelse kan rettes til adm. direktør Lasse Nyby på 96 34 40 11 eller til undertegnede på 96 34 42 36.
Venlig hilsen
Rune Brandt Børglum
IR-chef
Vedhæftede filer
- Nr. 31 - Finansielle resultater 1. kvartal 2024 - DK
- Nr. 31 - Kvartalsrapport 1. kvartal 2024 for Spar Nord
For at se dette indhold fra ml-eu.globenewswire.com, så skal du give din accept på toppen af denne side.
Information om GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg pressemeddelelser fra GlobeNewswire by notified
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra GlobeNewswire by notified
Constellation Brands to Present at the Bernstein 40th Annual Strategic Decisions Conference on Wednesday, May 29, 202416.5.2024 22:30:20 CEST | Press release
VICTOR, N.Y., May 16, 2024 (GLOBE NEWSWIRE) -- Constellation Brands, Inc. (NYSE: STZ), a leading beverage alcohol company, announced today that Bill Newlands, President and Chief Executive Officer, and Garth Hankinson, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Bernstein 40th Annual Strategic Decisions Conference on Wednesday, May 29, 2024 in New York, NY. The presentation is scheduled to begin at 2:30 p.m. EDT and is expected to cover the company’s strategic business initiatives, financial metrics, and operating performance, as well as outlook for the future. A live, listen-only webcast of the presentation will be available on the company’s investor relations website at ir.cbrands.com under the News & Events section. When the presentation begins, financial information discussed in the presentation, and a reconciliation of reported GAAP financial measures with comparable and other non-GAAP financial measures, will also be available
DBV Technologies Announces Results of its 2024 Combined General Meeting16.5.2024 22:30:00 CEST | Press release
Châtillon, France, May 16, 2024 DBV Technologies Announces Results of its 2024 Combined General Meeting Shareholders approved all proposed resolutions DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT) (the “Company”), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, held its Combined General Meeting (the “General Meeting”). The General Meeting was chaired by Michel de Rosen, Chairman of the Company. The Company’s shareholders approved all resolutions submitted by the Board of Directors. These resolutions and their results are posted on the Investors/Annual General Meetings section of the Company’s website: https://dbv-technologies.com/events/2024-annual-general-meeting/. About DBV Technologies DBV Technologies is a clinical-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with sign
Clean Motion AB delårsredogörelse för januari-mars 202416.5.2024 22:10:00 CEST | Pressemelding
Elfordonstillverkaren Clean Motion AB presenterar sin delårsrapport för januari-mars 2024. Bolaget redovisar en försäljning på 38 (45) TSEK och ett rörelseresultat exklusive avskrivningar (EBITDA) på -2 949 (-1 825) TSEK. Bolaget meddelar även att ett licensavtal är tecknat för tillverkning av Zbee i Indien samt att deras nya produktionslokal för EVIG i Jonsered nu är godkänd. Sofia Haby, VD kommenterar; ”Vi har jobbat intensivt under kvartalet med både typgodkännande-processen och flytt till nya lokaler. Kvartalet har präglats av de förseningar som vi drabbats av med vårt typgodkännande, vilket förhindrat försäljning i Europa. Jag kan nu med glädje meddela att det mest kritiska testet blev godkänt igår kväll! Under de senaste månaderna har vi jobbat med att färdigställa vår nya produktionslokal i Jonsered. Jag är övertygad om att vi genom att samla alla resurser under ett tak, kommer att åstadkomma stora effektivitetsförbättringar. Teamet har arbetat dedikerat med att säkerställa en s
Galapagos creates new subscription right plans16.5.2024 22:01:00 CEST | Press release
Mechelen, Belgium; 16 May 2024, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its Board of Directors created 1,614,000 subscription rights under new subscription right plans for the benefit of certain members of the personnel of the company and its subsidiaries. On 16 May 2024, the Board of Directors of Galapagos approved “Subscription Right Plan 2024 BE”, intended for members of personnel of the company, “Subscription Right Plan 2024 RMV,” intended for the employees of its French subsidiary, Galapagos SASU, and “Subscription Right Plan 2024 ROW”, primarily intended for the employees of its other non-Belgian subsidiaries, within the framework of the authorized capital. Under these subscription right plans, 1,614,000 subscription rights were created, subject to acceptances, and offered to the beneficiaries of the plans. The subscription rights have an exercise term of eight years as of the date of the offer and have an exercise price of €
Inventiva announces the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH16.5.2024 22:00:00 CEST | Press release
The Data Monitoring Committee recommended to continue the clinical trial without modification of the current protocol, based on the pre-planned review of safety data.The recommendation was based on the unblinded review by the DMC of safety data from more than 900 patients randomized in the main and exploratory cohorts, including more than 360 and 80 patients that have been treated for more than 48 and 72 weeks, respectively.The patient who experienced the adverse event of increased liver test results, which was reported as a SUSAR, has been without clinical symptoms throughout the period of observation and has fully recovered.The DMC review confirms the good safety profile of lanifibranor. Daix (France), Long Island City (New York, United States), May 16, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepa